禽流感(Avian influenza,AI)和马立克氏病(Marek′s disease,MD)是严重危害全球养禽业发展的两个主要病毒性传染病。目前,疫苗免疫是防控这两种病毒性疾病有效手段之一。在众多病毒活载体疫苗中,火鸡疱疹病毒(Herpesvirus of turkey,HVT...禽流感(Avian influenza,AI)和马立克氏病(Marek′s disease,MD)是严重危害全球养禽业发展的两个主要病毒性传染病。目前,疫苗免疫是防控这两种病毒性疾病有效手段之一。在众多病毒活载体疫苗中,火鸡疱疹病毒(Herpesvirus of turkey,HVT)以其独特的优势备受青睐,而以HVT表达禽流感病毒保护性抗原是目前的研究热点之一。本文对以HVT作为疫苗载体的优势和构建载体疫苗的影响因素(外源基因、启动子、复制非必需区的选择等)进行多方面分析,并对目前AI-HVT重组疫苗的研究进展进行综述。展开更多
A new kind of recombinant herpes simplex virus type 1 (HSV 1) was constructed. This recombinant, named HSV1 LaL, contained an unique packaging signal (“a" sequence) flanked by two loxP sites in parallel orientat...A new kind of recombinant herpes simplex virus type 1 (HSV 1) was constructed. This recombinant, named HSV1 LaL, contained an unique packaging signal (“a" sequence) flanked by two loxP sites in parallel orientation, named LaL, while the original packaging signals of HSV 1 were deleted. Based on a set of cosmids containing the entire HSV 1 genome except the “a" sequence, the LaL was inserted into HSV 1 UL44 gene on one of the cosmids, cos56, generating cos56/LaL. By co transfecting cos56/LaL with the other cosmids, HSV1 LaL was generated in the cells by recombination. By introducing cos56/LaL or HSV1 LaL respectively into E.coli or BHK cells that expressed Cre recombinase, LaLs on both of them were excised by Cre, which was proved by PCR detection. To study the potential use as helper virus in packaging amplicon vector, HSV1 LaL was compared with a control virus HSV1 lacZ that contained a lacZ gene in the UL44 gene. The titer of amplicon virus generated from HSV1 LaL infected BHK/Cre cells was basically the same as that from HSV1 lacZ infected cells, however,the former contained about 10 fold less helper virus than the later, while HSV1 LaL showed the same replication rate as HSV1 lacZ on standard cells, like BHK 21.展开更多
文摘禽流感(Avian influenza,AI)和马立克氏病(Marek′s disease,MD)是严重危害全球养禽业发展的两个主要病毒性传染病。目前,疫苗免疫是防控这两种病毒性疾病有效手段之一。在众多病毒活载体疫苗中,火鸡疱疹病毒(Herpesvirus of turkey,HVT)以其独特的优势备受青睐,而以HVT表达禽流感病毒保护性抗原是目前的研究热点之一。本文对以HVT作为疫苗载体的优势和构建载体疫苗的影响因素(外源基因、启动子、复制非必需区的选择等)进行多方面分析,并对目前AI-HVT重组疫苗的研究进展进行综述。
文摘A new kind of recombinant herpes simplex virus type 1 (HSV 1) was constructed. This recombinant, named HSV1 LaL, contained an unique packaging signal (“a" sequence) flanked by two loxP sites in parallel orientation, named LaL, while the original packaging signals of HSV 1 were deleted. Based on a set of cosmids containing the entire HSV 1 genome except the “a" sequence, the LaL was inserted into HSV 1 UL44 gene on one of the cosmids, cos56, generating cos56/LaL. By co transfecting cos56/LaL with the other cosmids, HSV1 LaL was generated in the cells by recombination. By introducing cos56/LaL or HSV1 LaL respectively into E.coli or BHK cells that expressed Cre recombinase, LaLs on both of them were excised by Cre, which was proved by PCR detection. To study the potential use as helper virus in packaging amplicon vector, HSV1 LaL was compared with a control virus HSV1 lacZ that contained a lacZ gene in the UL44 gene. The titer of amplicon virus generated from HSV1 LaL infected BHK/Cre cells was basically the same as that from HSV1 lacZ infected cells, however,the former contained about 10 fold less helper virus than the later, while HSV1 LaL showed the same replication rate as HSV1 lacZ on standard cells, like BHK 21.
